董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Hale | 男 | Director and Lead Director | 77 | 7.87万美元 | 1.74 | 2026-05-27 |
| Wendell Wierenga | 男 | Director | 78 | 5.57万美元 | 0.14 | 2026-05-27 |
| Kathleen Scott | 女 | Director | 57 | 6.07万美元 | 0.14 | 2026-05-27 |
| Andrew Sandler | 男 | Director | 61 | 5.47万美元 | 0.14 | 2026-05-27 |
| Brittany Bradrick | 女 | Director | 56 | 5.32万美元 | 0.14 | 2026-05-27 |
| Gerald T. Proehl | 男 | Chairman,Chief Executive Officer,Director and President | 67 | 47.25万美元 | 69.49 | 2026-05-27 |
| Steven Mento | 男 | Director | 74 | 4.97万美元 | 0.14 | 2026-05-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher J. Nardo | 男 | Chief Development Officer and Senior Vice President | 61 | 53.71万美元 | 0.09 | 2026-05-27 |
| Maria Bedoya Toro Munera | 女 | Senior Vice President, Regulatory Affairs & Quality Assurance | 74 | 2.70万美元 | 未持股 | 2026-05-27 |
| Kyri K. Van Hoose | 女 | Chief Financial Officer and Senior Vice President | 48 | 50.85万美元 | 13.13 | 2026-05-27 |
| Gerald T. Proehl | 男 | Chairman,Chief Executive Officer,Director and President | 67 | 47.25万美元 | 69.49 | 2026-05-27 |
董事简历
中英对照 | 中文 | 英文- David Hale
-
David Hale是我们的联合创始人，自2014年12月起担任董事会成员，自2021年4月起担任首席董事。Hale先生是Hale BioPharma Ventures，LLC的董事长兼首席执行官，该公司是一家私人公司，专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展。Hale先生是一位连续企业家，参与了许多成功的生物医药公司的组建和发展。他曾担任Santarus，Inc.（一家专业生物制药公司）的董事长（2004年以来），以及Santarus’；的董事会成员（2000年以来）（2014年被SalixPharmaceuticals，Ltd.收购之前），以及SkinMedica，Inc.的董事长（2012年出售给AllerganMicromet，Inc.之前），在2012年出售给安进公司之前，SomaxonPharmaceuticals，Inc.在2013年出售给Pernix Therapeutics Holdings Inc.之前，Crisi Medical Systems，Inc.在2015年出售给Becton Dickinson&Company和Agility Clinical之前，Inc.于2017年出售给Precision Medicine Inc.之前。Hale先生是Adigica Health，Inc.，Zerigo Health，Inc.，OncternalTherapeutics，Inc.，Neurana Pharmaceuticals，Inc.的联合创始人兼董事长。他也是Neurelis Pharmaceuticals，Inc.和Recros Medica，Inc.的联合创始人兼董事，是Cadence Inc.、Evoke Pharma Inc.、Elevation Pharmaceutical Inc.和Zogenix Inc.的联合创始人。Hale是Biocom和Connect的联合创始人和董事会成员，也是生物技术产业组织Bio和生物技术研究所的前董事会成员。他自1986年以来一直在Rady Children’；S Hospital的董事会任职，包括从2011年到2015年担任董事会主席，是Rady Children’；S Institute of Genomic Medicine的创始人兼董事长。他是UCSD雷迪管理学院院长和圣地亚哥经济发展公司的顾问委员会的成员。
David Hale is Dermata Therapeutics, Inc.'s co founder and has served as a member of Dermata Therapeutics, Inc.'s board of directors since December 2014, and as Lead Director since April 2021. Mr. Hale is Chairman and CEO of Hale BioPharma Ventures, LLC a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of successful biomedical companies. He served as the Chairman of Santarus, Inc., a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000, prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014, and as Chairman of SkinMedica, Inc., prior to its sale to Allergan in 2012, Micromet, Inc., prior to its sale to Amgen Inc. in 2012, Somaxon Pharmaceuticals, Inc., prior to its sale to Pernix Therapeutics Holdings Inc. in 2013, Crisi Medical Systems, Inc., prior to its sale to Becton Dickinson & Company in 2015, and Agility Clinical, Inc. prior to its sale to Precision Medicine Inc. in 2017. Mr. Hale is also a co founder and currently serves as a director of Neurelis, Inc., a private company, and is a co founder of Zerigo Health, Oncternal Therapeutics, Inc., Inc., Cadence, Inc., Elevation Pharma, Inc., and Zogenix, Inc. Mr. Hale is a co founder and serves on the Board of Directors of BIOCOM and CONNECT and is a former member of the Board of the Biotechnology Innovation Organization (BIO), and the Biotechnology Institute. He has served on the Board of Rady Children's Hospital since 1986, including Chairman of the Board from 2011 to 2015, and is founder and Chairman of the Rady Children's Institute of Genomic Medicine. - David Hale是我们的联合创始人，自2014年12月起担任董事会成员，自2021年4月起担任首席董事。Hale先生是Hale BioPharma Ventures，LLC的董事长兼首席执行官，该公司是一家私人公司，专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展。Hale先生是一位连续企业家，参与了许多成功的生物医药公司的组建和发展。他曾担任Santarus，Inc.（一家专业生物制药公司）的董事长（2004年以来），以及Santarus’；的董事会成员（2000年以来）（2014年被SalixPharmaceuticals，Ltd.收购之前），以及SkinMedica，Inc.的董事长（2012年出售给AllerganMicromet，Inc.之前），在2012年出售给安进公司之前，SomaxonPharmaceuticals，Inc.在2013年出售给Pernix Therapeutics Holdings Inc.之前，Crisi Medical Systems，Inc.在2015年出售给Becton Dickinson&Company和Agility Clinical之前，Inc.于2017年出售给Precision Medicine Inc.之前。Hale先生是Adigica Health，Inc.，Zerigo Health，Inc.，OncternalTherapeutics，Inc.，Neurana Pharmaceuticals，Inc.的联合创始人兼董事长。他也是Neurelis Pharmaceuticals，Inc.和Recros Medica，Inc.的联合创始人兼董事，是Cadence Inc.、Evoke Pharma Inc.、Elevation Pharmaceutical Inc.和Zogenix Inc.的联合创始人。Hale是Biocom和Connect的联合创始人和董事会成员，也是生物技术产业组织Bio和生物技术研究所的前董事会成员。他自1986年以来一直在Rady Children’；S Hospital的董事会任职，包括从2011年到2015年担任董事会主席，是Rady Children’；S Institute of Genomic Medicine的创始人兼董事长。他是UCSD雷迪管理学院院长和圣地亚哥经济发展公司的顾问委员会的成员。
- David Hale is Dermata Therapeutics, Inc.'s co founder and has served as a member of Dermata Therapeutics, Inc.'s board of directors since December 2014, and as Lead Director since April 2021. Mr. Hale is Chairman and CEO of Hale BioPharma Ventures, LLC a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of successful biomedical companies. He served as the Chairman of Santarus, Inc., a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000, prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014, and as Chairman of SkinMedica, Inc., prior to its sale to Allergan in 2012, Micromet, Inc., prior to its sale to Amgen Inc. in 2012, Somaxon Pharmaceuticals, Inc., prior to its sale to Pernix Therapeutics Holdings Inc. in 2013, Crisi Medical Systems, Inc., prior to its sale to Becton Dickinson & Company in 2015, and Agility Clinical, Inc. prior to its sale to Precision Medicine Inc. in 2017. Mr. Hale is also a co founder and currently serves as a director of Neurelis, Inc., a private company, and is a co founder of Zerigo Health, Oncternal Therapeutics, Inc., Inc., Cadence, Inc., Elevation Pharma, Inc., and Zogenix, Inc. Mr. Hale is a co founder and serves on the Board of Directors of BIOCOM and CONNECT and is a former member of the Board of the Biotechnology Innovation Organization (BIO), and the Biotechnology Institute. He has served on the Board of Rady Children's Hospital since 1986, including Chairman of the Board from 2011 to 2015, and is founder and Chairman of the Rady Children's Institute of Genomic Medicine.
- Wendell Wierenga
-
Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from August 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held various positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently was on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively. Dr. Wierenga was selected as a director due to his industry and executive business experience. - Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
- Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from August 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held various positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently was on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively. Dr. Wierenga was selected as a director due to his industry and executive business experience.
- Kathleen Scott
-
Kathleen Scott将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Scott女士目前是Neurana Pharmaceuticals，Inc.（一家私人生物技术公司）的首席财务官。在Neurana之前，Scott女士从2014年8月到2021年4月担任Recros Medica Health的首席财务官，从2016年2月到2021年3月担任Clarify Medical公司的董事，从2014年8月到2016年12月担任Oncternal Therapeutics公司的董事，从2016年3月到2016年5月担任McRevena公司的董事，从2014年8月到2016年8月以及2010年3月至2014年11月的生物盈余。在加入BioSurplus之前，Scott女士是RA Capital Advisors的合伙人，这是一家圣地亚哥的私人投资银行，提供财务咨询服务。从1994年12月到2010年7月，Scott女士在RA Capital Advisors工作了15年多，为广泛的公司客户完成了数十亿美元的合并、收购、资产剥离和重组。Scott女士的职业生涯始于在Arthur Andersen’；的圣地亚哥办事处担任审计员，专注于公共和私人客户。Scott女士是圣迭戈县基督教青年会的董事会主席，是注册会计师和CFA特许持有人。斯科特女士以优异成绩从加州大学洛杉矶分校毕业，获得经济学/商学学士学位。
Kathleen Scott became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Ms. Scott is currently the Chief Financial Officer of ARS Pharmaceuticals, Inc., a publicly traded biotech company (Nasdaq: SPRY). Prior to ARS Pharmaceuticals, Ms. Scott was the Chief Financial Officer of Neurana Pharmaceuticals from January 2017 to March 2022, Recros Medica from August 2014 to April 2021, Adigica Health from February 2016 to March 2021, Clarify Medical from August 2014 to December 2016, Oncternal Therapeutics from March 2016 to May 2016, MDRejuvena from August 2014 to August 2016, and BioSurplus from March 2010 to November 2014. Prior to BioSurplus, Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. Ms. Scott spent over 15 years with RA Capital Advisors, from December 1994 to July 2010, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen's San Diego office, focusing on both public and private clients. Ms. Scott was the past board chair and is a current director of the YMCA of San Diego County. In September of 2023 Ms. Scott became a director of NKGen Biotech, Inc. (OTCQX: NKGN) and is currently the chair of its audit and compensation committees. Ms. Scott is a CPA and CFA charter holder and graduated magna cum laude from UCLA with a B.S. in economics/business. - Kathleen Scott将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Scott女士目前是Neurana Pharmaceuticals，Inc.（一家私人生物技术公司）的首席财务官。在Neurana之前，Scott女士从2014年8月到2021年4月担任Recros Medica Health的首席财务官，从2016年2月到2021年3月担任Clarify Medical公司的董事，从2014年8月到2016年12月担任Oncternal Therapeutics公司的董事，从2016年3月到2016年5月担任McRevena公司的董事，从2014年8月到2016年8月以及2010年3月至2014年11月的生物盈余。在加入BioSurplus之前，Scott女士是RA Capital Advisors的合伙人，这是一家圣地亚哥的私人投资银行，提供财务咨询服务。从1994年12月到2010年7月，Scott女士在RA Capital Advisors工作了15年多，为广泛的公司客户完成了数十亿美元的合并、收购、资产剥离和重组。Scott女士的职业生涯始于在Arthur Andersen’；的圣地亚哥办事处担任审计员，专注于公共和私人客户。Scott女士是圣迭戈县基督教青年会的董事会主席，是注册会计师和CFA特许持有人。斯科特女士以优异成绩从加州大学洛杉矶分校毕业，获得经济学/商学学士学位。
- Kathleen Scott became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Ms. Scott is currently the Chief Financial Officer of ARS Pharmaceuticals, Inc., a publicly traded biotech company (Nasdaq: SPRY). Prior to ARS Pharmaceuticals, Ms. Scott was the Chief Financial Officer of Neurana Pharmaceuticals from January 2017 to March 2022, Recros Medica from August 2014 to April 2021, Adigica Health from February 2016 to March 2021, Clarify Medical from August 2014 to December 2016, Oncternal Therapeutics from March 2016 to May 2016, MDRejuvena from August 2014 to August 2016, and BioSurplus from March 2010 to November 2014. Prior to BioSurplus, Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. Ms. Scott spent over 15 years with RA Capital Advisors, from December 1994 to July 2010, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen's San Diego office, focusing on both public and private clients. Ms. Scott was the past board chair and is a current director of the YMCA of San Diego County. In September of 2023 Ms. Scott became a director of NKGen Biotech, Inc. (OTCQX: NKGN) and is currently the chair of its audit and compensation committees. Ms. Scott is a CPA and CFA charter holder and graduated magna cum laude from UCLA with a B.S. in economics/business.
- Andrew Sandler
-
Andrew Sandler将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Sandler博士自2017年9月起担任Kiadis Pharma N.V.的首席医疗官。在Kiadis之前，Sandler博士于2016年1月至2017年6月担任Medivation的高级副总裁，负责医疗事务。2010年10月至2015年4月，Sandler博士在Dendreon Pharmaceuticals担任多个职位，包括首席医疗官和西雅图网站负责人。加入Dendreon之前，Sandler博士从2008年9月到2010年4月担任Spectrum Pharmaceuticals的首席医疗官，从2008年2月到2010年2月担任Bayer医疗保健Pharmaceuticals的副总裁，负责全球医疗事务，负责肿瘤学。Sandler博士还从2003年10月到2008年8月在Berlex Oncology/Schering AG和从1999年10月到2003年6月在Seagen，Inc.担任多个职位。从1994年7月到1996年6月，Sandler博士是加州大学旧金山分校（UCSF）血液学/医学肿瘤学研究员。1990年7月至1994年6月，他在纽约西奈山医院（Mt.Sinai Hospital，New York，NY）实习，担任住院医师和首席住院医师。1986年7月至1990年6月，Sandler博士在西奈山医学院（Icahn School of Medicine at Mt.Sinai）获得医学博士学位。此外，他于1986年毕业于罗切斯特大学，获得神经科学学士学位。
Andrew Sandler became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Dr. Sandler served as Chief Medical Officer of Alpine Immune Sciences, Inc. (Nasdaq: ALPN) from August 2022 until June 2024. From September 2017 until June 2022, Dr. Sandler served as Chief Medical Officer at Kiadis Pharma N.V. Prior to Kiadis, Dr. Sandler was Senior Vice President, Medical Affairs at Medivation (acquired by Pfizer) from January 2016 to June 2017. Dr. Sandler held various additional roles including Chief Medical Officer and Seattle Site Head at Dendreon Pharmaceuticals from October 2010 to April 2015. Prior to Dendreon, Dr. Sandler was Chief Medical Officer at Spectrum Pharmaceuticals from September 2008 to April 2010, and Vice President, Head of Global Medical Affairs, Oncology for Bayer Healthcare Pharmaceuticals from February 2008 to February 2010. Dr. Sandler also held various positions at Berlex Oncology/Schering AG from October 2003 to August 2008, and Seagen, Inc. from October 1999 to June 2003. Dr. Sandler was a Fellow in Hematology/Medical Oncology at the University of California, San Francisco (UCSF) from July 1994 to June 1996. He did his Internship, Residency, and Chief Residency at Mt. Sinai Hospital in New York, NY from July 1990 to June 1994. Dr. Sandler attended and received his MD degree from Mount Sinai School of Medicine (Icahn School of Medicine at Mt. Sinai) from July 1986 to June 1990. In addition, he graduated from the University of Rochester with a B.S. degree in Neuroscience in 1986. Dr. Sandler was selected as a director due to his experience in the biotechnology and pharmaceutical industries as well as his leadership experience. - Andrew Sandler将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Sandler博士自2017年9月起担任Kiadis Pharma N.V.的首席医疗官。在Kiadis之前，Sandler博士于2016年1月至2017年6月担任Medivation的高级副总裁，负责医疗事务。2010年10月至2015年4月，Sandler博士在Dendreon Pharmaceuticals担任多个职位，包括首席医疗官和西雅图网站负责人。加入Dendreon之前，Sandler博士从2008年9月到2010年4月担任Spectrum Pharmaceuticals的首席医疗官，从2008年2月到2010年2月担任Bayer医疗保健Pharmaceuticals的副总裁，负责全球医疗事务，负责肿瘤学。Sandler博士还从2003年10月到2008年8月在Berlex Oncology/Schering AG和从1999年10月到2003年6月在Seagen，Inc.担任多个职位。从1994年7月到1996年6月，Sandler博士是加州大学旧金山分校（UCSF）血液学/医学肿瘤学研究员。1990年7月至1994年6月，他在纽约西奈山医院（Mt.Sinai Hospital，New York，NY）实习，担任住院医师和首席住院医师。1986年7月至1990年6月，Sandler博士在西奈山医学院（Icahn School of Medicine at Mt.Sinai）获得医学博士学位。此外，他于1986年毕业于罗切斯特大学，获得神经科学学士学位。
- Andrew Sandler became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Dr. Sandler served as Chief Medical Officer of Alpine Immune Sciences, Inc. (Nasdaq: ALPN) from August 2022 until June 2024. From September 2017 until June 2022, Dr. Sandler served as Chief Medical Officer at Kiadis Pharma N.V. Prior to Kiadis, Dr. Sandler was Senior Vice President, Medical Affairs at Medivation (acquired by Pfizer) from January 2016 to June 2017. Dr. Sandler held various additional roles including Chief Medical Officer and Seattle Site Head at Dendreon Pharmaceuticals from October 2010 to April 2015. Prior to Dendreon, Dr. Sandler was Chief Medical Officer at Spectrum Pharmaceuticals from September 2008 to April 2010, and Vice President, Head of Global Medical Affairs, Oncology for Bayer Healthcare Pharmaceuticals from February 2008 to February 2010. Dr. Sandler also held various positions at Berlex Oncology/Schering AG from October 2003 to August 2008, and Seagen, Inc. from October 1999 to June 2003. Dr. Sandler was a Fellow in Hematology/Medical Oncology at the University of California, San Francisco (UCSF) from July 1994 to June 1996. He did his Internship, Residency, and Chief Residency at Mt. Sinai Hospital in New York, NY from July 1990 to June 1994. Dr. Sandler attended and received his MD degree from Mount Sinai School of Medicine (Icahn School of Medicine at Mt. Sinai) from July 1986 to June 1990. In addition, he graduated from the University of Rochester with a B.S. degree in Neuroscience in 1986. Dr. Sandler was selected as a director due to his experience in the biotechnology and pharmaceutical industries as well as his leadership experience.
- Brittany Bradrick
-
布列塔尼·布莱德里克于2022年1月成为董事。Bradrick女士自2022年9月起担任Neurelis公司首席运营官兼首席财务官，自2021年10月起担任首席财务官。在加入Neurelis公司之前，Bradrick女士于2020年6月至2021年9月担任ViaCyte公司首席运营官兼首席财务官。在加入Viacyte之前，Bradrick女士曾在Insulet Corporation担任战略和企业发展职位，2016年至2020年担任战略与企业发展副总裁，并在雅培实验室（纽约证券交易所代码：ABT）担任业务发展与联盟管理总监。在担任这些职务之前，Bradrick女士曾于1997年至2007年在Piper Jaffray、瑞士信贷和大通证券担任生命科学行业的投资银行家。布莱德里克女士的职业生涯始于联邦储备银行审查员。Bradrick女士拥有康奈尔大学约翰逊管理研究生院的工商管理硕士学位和密苏里大学工商管理学士学位。Bradrick女士因其丰富的行业和金融经验而被选为董事。
Brittany Bradrick became a director in January 2022. Ms. Bradrick has served as the Chief Operating Officer and Chief Financial Officer of Neurelis, Inc. since September 2022 and the Chief Financial Officer since October 2021. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte Inc. from June 2020 to September 2021. Prior to ViaCyte, Ms. Bradrick served in strategy and corporate development positions at Insulet Corporation as Vice President, Strategy & Corporate Development from 2016 to 2020 and as Director, Business Development & Alliance Management at Abbott Laboratories (NYSE: ABT). Ms. Bradrick was appointed as a director to Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) on May 4, 2022, and was appointed as the chairperson to the audit committee on May 25, 2022. Prior to these positions, Ms. Bradrick was an investment banker for the life science industry at Piper Jaffray, Credit Suisse, and Chase Securities from 1997 to 2007. Ms. Bradrick began her career as a Federal Reserve Bank Examiner. Ms. Bradrick holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri. - 布列塔尼·布莱德里克于2022年1月成为董事。Bradrick女士自2022年9月起担任Neurelis公司首席运营官兼首席财务官，自2021年10月起担任首席财务官。在加入Neurelis公司之前，Bradrick女士于2020年6月至2021年9月担任ViaCyte公司首席运营官兼首席财务官。在加入Viacyte之前，Bradrick女士曾在Insulet Corporation担任战略和企业发展职位，2016年至2020年担任战略与企业发展副总裁，并在雅培实验室（纽约证券交易所代码：ABT）担任业务发展与联盟管理总监。在担任这些职务之前，Bradrick女士曾于1997年至2007年在Piper Jaffray、瑞士信贷和大通证券担任生命科学行业的投资银行家。布莱德里克女士的职业生涯始于联邦储备银行审查员。Bradrick女士拥有康奈尔大学约翰逊管理研究生院的工商管理硕士学位和密苏里大学工商管理学士学位。Bradrick女士因其丰富的行业和金融经验而被选为董事。
- Brittany Bradrick became a director in January 2022. Ms. Bradrick has served as the Chief Operating Officer and Chief Financial Officer of Neurelis, Inc. since September 2022 and the Chief Financial Officer since October 2021. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte Inc. from June 2020 to September 2021. Prior to ViaCyte, Ms. Bradrick served in strategy and corporate development positions at Insulet Corporation as Vice President, Strategy & Corporate Development from 2016 to 2020 and as Director, Business Development & Alliance Management at Abbott Laboratories (NYSE: ABT). Ms. Bradrick was appointed as a director to Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) on May 4, 2022, and was appointed as the chairperson to the audit committee on May 25, 2022. Prior to these positions, Ms. Bradrick was an investment banker for the life science industry at Piper Jaffray, Credit Suisse, and Chase Securities from 1997 to 2007. Ms. Bradrick began her career as a Federal Reserve Bank Examiner. Ms. Bradrick holds an M.B.A. from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.
- Gerald T. Proehl
-
Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
Gerald T. Proehl became a director and Dermata Therapeutics, Inc.'s President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc.'s Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical industry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). Mr. Proehl was selected as an officer and director due to his leadership experience at other companies and his history of founding and operating specialty pharmaceutical companies. - Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
- Gerald T. Proehl became a director and Dermata Therapeutics, Inc.'s President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc.'s Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical industry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). Mr. Proehl was selected as an officer and director due to his leadership experience at other companies and his history of founding and operating specialty pharmaceutical companies.
- Steven Mento
-
Steven Mento，2005年5月起担任公司董事会成员。2005年7月起，他担任生物科技公司Conatus Pharmaceuticals Inc.的总裁和首席执行官，该公司从事肝脏疾病的人类疗法开发。1997至2005年，他担任Idun Pharmaceuticals的总裁和首席执行官。此前，1982至1992年，他在American Cyanamid Company担任多个职位，最后一职是在其业务单元Lederle-Praxis Biologicals担任病毒疫苗研究和开发主管。1992年1月，他加入Viagene, Inc.，担任研发部副总裁。他负责带领公司从基本研究转变，通过发起第一家由公司资助的基因疗法新兴领域的阶段I和阶段II临床试验。1995年10月，Chiron Corporation 收购了Viagene, Inc.，重命名为Chiron Viagene, Inc.。他现在BIOCOM、the BIOCOM Institute、the Biotechnology Industry Organization（BIO）， 以及BIO ECS Governing Body的成员the BIO Health Section Governing Body、SDSU科学咨询委员会下的the Donald P. Shiley BioScience Center以及Cal State San Marcos咨询委员会等的董事会任职。 他获有Rutgers University微生物学专业学士、硕士、博士学位。他在University of Toronto完成了体细胞遗传学的博士后研究。
Steven Mento became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Dr. Mento served as President and Chief Executive Officer of Histogen Inc. from March 2023 until September 2023. He assumed these positions in March of 2023. From November 2021 to October 2023, Dr. Mento served as Executive Chairman and Interim President and CEO of Histogen Inc. (Nasdaq: HSTO). Since July 2005, Dr. Mento has served as a director on the board of directors of Conatus Pharmaceuticals, Inc. and from July 2005 to December 2012, Dr. Mento served as chairman of Conatus' board of directors. Dr. Mento was a co founder of Conatus and served as its President and Chief Executive Officer from July 2005 until its merger with Histogen Inc. in May 2020. Dr. Mento has over 35 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, Dr. Mento was President, Chief Executive Officer and a member of the board of directors of Idun Pharmaceuticals, Inc. Dr. Mento guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, Dr. Mento served as President of Chiron Viagene, Inc. (subsequently Chiron Technologies, Center for Gene Therapy) from 1995 to 1997, and Vice President of Chiron Corporation from 1995 to 1997. Dr. Mento was Vice President of research and development at Viagene from 1992 to 1995. Prior to Viagene, Dr. Mento held various positions at American Cyanamid Company from 1982 to 1992, including as Director of Viral Vaccine Research and Development at Lederle Praxis Biologicals, a business unit of American Cyanamid. Dr. Mento currently serves on the board of directors of Histogen, BIOCOM California and various academic and charitable organizations. He previously served on the boards of Biotechnology Innovation Organization, BIO Emerging Companies Section Governing Board, BIO Health Section Governing Board, and Sangamo Biosciences, Inc. Dr. Mento holds a Ph.D. and M.S., both in Microbiology, from Rutgers University, and a B.A. in Microbiology from Rutgers College. Dr. Mento was selected as a director due to his experience in the biotechnology and pharmaceutical industries, including executive leadership experience at several pharmaceutical companies. - Steven Mento，2005年5月起担任公司董事会成员。2005年7月起，他担任生物科技公司Conatus Pharmaceuticals Inc.的总裁和首席执行官，该公司从事肝脏疾病的人类疗法开发。1997至2005年，他担任Idun Pharmaceuticals的总裁和首席执行官。此前，1982至1992年，他在American Cyanamid Company担任多个职位，最后一职是在其业务单元Lederle-Praxis Biologicals担任病毒疫苗研究和开发主管。1992年1月，他加入Viagene, Inc.，担任研发部副总裁。他负责带领公司从基本研究转变，通过发起第一家由公司资助的基因疗法新兴领域的阶段I和阶段II临床试验。1995年10月，Chiron Corporation 收购了Viagene, Inc.，重命名为Chiron Viagene, Inc.。他现在BIOCOM、the BIOCOM Institute、the Biotechnology Industry Organization（BIO）， 以及BIO ECS Governing Body的成员the BIO Health Section Governing Body、SDSU科学咨询委员会下的the Donald P. Shiley BioScience Center以及Cal State San Marcos咨询委员会等的董事会任职。 他获有Rutgers University微生物学专业学士、硕士、博士学位。他在University of Toronto完成了体细胞遗传学的博士后研究。
- Steven Mento became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Dr. Mento served as President and Chief Executive Officer of Histogen Inc. from March 2023 until September 2023. He assumed these positions in March of 2023. From November 2021 to October 2023, Dr. Mento served as Executive Chairman and Interim President and CEO of Histogen Inc. (Nasdaq: HSTO). Since July 2005, Dr. Mento has served as a director on the board of directors of Conatus Pharmaceuticals, Inc. and from July 2005 to December 2012, Dr. Mento served as chairman of Conatus' board of directors. Dr. Mento was a co founder of Conatus and served as its President and Chief Executive Officer from July 2005 until its merger with Histogen Inc. in May 2020. Dr. Mento has over 35 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, Dr. Mento was President, Chief Executive Officer and a member of the board of directors of Idun Pharmaceuticals, Inc. Dr. Mento guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, Dr. Mento served as President of Chiron Viagene, Inc. (subsequently Chiron Technologies, Center for Gene Therapy) from 1995 to 1997, and Vice President of Chiron Corporation from 1995 to 1997. Dr. Mento was Vice President of research and development at Viagene from 1992 to 1995. Prior to Viagene, Dr. Mento held various positions at American Cyanamid Company from 1982 to 1992, including as Director of Viral Vaccine Research and Development at Lederle Praxis Biologicals, a business unit of American Cyanamid. Dr. Mento currently serves on the board of directors of Histogen, BIOCOM California and various academic and charitable organizations. He previously served on the boards of Biotechnology Innovation Organization, BIO Emerging Companies Section Governing Board, BIO Health Section Governing Board, and Sangamo Biosciences, Inc. Dr. Mento holds a Ph.D. and M.S., both in Microbiology, from Rutgers University, and a B.A. in Microbiology from Rutgers College. Dr. Mento was selected as a director due to his experience in the biotechnology and pharmaceutical industries, including executive leadership experience at several pharmaceutical companies.
高管简历
中英对照 | 中文 | 英文- Christopher J. Nardo
Christopher J.Nardo于2015年6月成为我们的高级副总裁。Nardo博士在制药行业拥有超过15年的经验。从2010年9月到2015年5月，Nardo博士在Allergan，PLC担任越来越多的职位，最初领导Botox的临床开发，用于治疗从第3阶段到产品批准和推出的活动过度的膀胱癌，并最终领导皮肤科治疗领域内的美学小组的临床开发，以及担任Allergan/Medytox合作的全球开发团队负责人，包括担任AGN/MTX联合开发委员会主席。从2006年到2010年，Nardo博士担任SpectrumPharmaceuticals，Inc.临床操作和生物统计学副总裁。纳斯达克:SPPI。在此之前，Nardo博士在Cancervax Corporation，the Immune Response Corporation和Procter and Gamble Company（NYSE:PG）担任过各种临床开发领导职务。Nardo博士在北卡罗来纳大学教堂山分校吉林斯公共卫生学院获得流行病学博士学位，在圣地亚哥州立大学公共卫生学院获得流行病学和生物统计学硕士学位，在Loyola Marymount University获得生物学学士学位。
Christopher J. Nardo became Dermata Therapeutics, Inc.'s Senior Vice President and Chief Development Officer in July 2022, and previously was Dermata Therapeutics, Inc.'s Senior Vice President of Development beginning in June 2015. Dr. Nardo has more than 25 years' experience in the biopharmaceutical industry and has successfully filed more than a dozen marketing applications in the United States, Europe, Canada, Australia and Japan. His experience spans pre clinical work through Phase 4 drug development of both small molecules and biologics for a broad range of therapeutic areas including: dermatology, ophthalmology, oncology, antiviral, urology, auto immune and cardiology. From 2010 to 2015, Dr. Nardo was Senior Director of Clinical Development at Allergan where he had responsibility for the conduct, submission, and approval of several global drug development programs, involving multiple dermatology assets, which included several new indications for BOTOX. From 2005 to 2010, Dr. Nardo served as Vice President of Clinical Operations at Spectrum Pharmaceuticals where he worked on developing new therapeutic opportunities in oncology and urology, including Fusilev and Zevalin. Prior to joining Spectrum, Dr. Nardo held several clinical development positions with increasing responsibility at CancerVax Corporation, The Immune Response Corporation, and Procter and Gamble. Dr. Nardo earned a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill, an M.P.H. from San Diego State University, and a B.S. (Biology) from Loyola Marymount University.- Christopher J.Nardo于2015年6月成为我们的高级副总裁。Nardo博士在制药行业拥有超过15年的经验。从2010年9月到2015年5月，Nardo博士在Allergan，PLC担任越来越多的职位，最初领导Botox的临床开发，用于治疗从第3阶段到产品批准和推出的活动过度的膀胱癌，并最终领导皮肤科治疗领域内的美学小组的临床开发，以及担任Allergan/Medytox合作的全球开发团队负责人，包括担任AGN/MTX联合开发委员会主席。从2006年到2010年，Nardo博士担任SpectrumPharmaceuticals，Inc.临床操作和生物统计学副总裁。纳斯达克:SPPI。在此之前，Nardo博士在Cancervax Corporation，the Immune Response Corporation和Procter and Gamble Company（NYSE:PG）担任过各种临床开发领导职务。Nardo博士在北卡罗来纳大学教堂山分校吉林斯公共卫生学院获得流行病学博士学位，在圣地亚哥州立大学公共卫生学院获得流行病学和生物统计学硕士学位，在Loyola Marymount University获得生物学学士学位。
- Christopher J. Nardo became Dermata Therapeutics, Inc.'s Senior Vice President and Chief Development Officer in July 2022, and previously was Dermata Therapeutics, Inc.'s Senior Vice President of Development beginning in June 2015. Dr. Nardo has more than 25 years' experience in the biopharmaceutical industry and has successfully filed more than a dozen marketing applications in the United States, Europe, Canada, Australia and Japan. His experience spans pre clinical work through Phase 4 drug development of both small molecules and biologics for a broad range of therapeutic areas including: dermatology, ophthalmology, oncology, antiviral, urology, auto immune and cardiology. From 2010 to 2015, Dr. Nardo was Senior Director of Clinical Development at Allergan where he had responsibility for the conduct, submission, and approval of several global drug development programs, involving multiple dermatology assets, which included several new indications for BOTOX. From 2005 to 2010, Dr. Nardo served as Vice President of Clinical Operations at Spectrum Pharmaceuticals where he worked on developing new therapeutic opportunities in oncology and urology, including Fusilev and Zevalin. Prior to joining Spectrum, Dr. Nardo held several clinical development positions with increasing responsibility at CancerVax Corporation, The Immune Response Corporation, and Procter and Gamble. Dr. Nardo earned a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill, an M.P.H. from San Diego State University, and a B.S. (Biology) from Loyola Marymount University.
- Maria Bedoya Toro Munera
Maria Bedoya Toro Munera于2016年1月成为我们的监管事务和质量保证高级副总裁。Bedoya Toro Munera博士在制药行业的监管合规、质量控制和质量保证方面拥有超过30年的经验。从2014年到2015年被出售给Celgene，Bedoya Toro Munera博士担任Receptos Inc.的监管事务和质量保证高级副总裁。Receptos，Inc.之前，2007年6月至2014年1月，Bedoya Toro Munera博士担任Santarus，Inc.监管事务和质量保证高级副总裁。她此前曾担任Eisai Medical Research Inc.的监管事务高级总监（从2006年11月到2007年5月），从Ligand Pharmaceuticals，Inc.跳槽到Eisai，当时Ligand于2006年11月将其肿瘤产品剥离给Eisai。2003年至2006年，Bedoya Toro Munera博士担任Ligand全球监管事务和合规高级总监。从2000年到2003年，她担任Baxter Hyland Immuno的全球监管事务总监。从1998年到2000年，她在BASF BioResearch Corporation担任监管事务/质量总监，从1996年到1998年，她在Amylin Pharmaceuticals担任质量保证和监管合规总监。从1988年到1996年，Bedoya Toro Munera博士在Rhone-Poulenc Rorer工作，在法规合规、质量保证、质量控制和合规方面担任多个日益负责的职位。Bedoya Toro Munera博士拥有芝加哥大学工商管理硕士学位，俄亥俄大学生物分析化学博士学位。此外，她拥有西密歇根大学生物分析化学硕士学位和化学学士学位。
Maria Bedoya Toro Munera became Dermata Therapeutics, Inc.'s Senior Vice President of Regulatory Affairs and Qualit Assurance in January 2016. Dr. Bedoya Toro Munera has more than 30 years of experience in regulatory compliance, quality control and quality assurance within the pharmaceutical industry. From 2014 until its sale to Celgene in 2015, Dr. Bedoya Toro Munera served as Senior Vice President, Regulatory Affairs and Quality Assurance at Receptos Inc. Prior to Receptos, Inc., Dr. Bedoya Toro Munera served as Senior Vice President of Regulatory Affairs and Quality Assurance at Santarus, Inc. from June 2007 to January 2014. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc., from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya Toro Munera worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006. From 2000 to 2003, she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000, Dr. Bedoya Toro Munera worked at BASF Bioresearch Corporation as Director, Regulatory Affairs/Quality, and from 1996 to 1998, she worked as Director, Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996, Dr. Bedoya Toro Munera worked at Rhone Poulenc Rorer in a number of increasingly responsible positions in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya Toro Munera holds an M.B.A. from the University of Chicago, and a Ph.D. in bio analytical chemistry from Ohio University. In addition, she has a M.A. in bio analytical chemistry and a B.S. in chemistry from Western Michigan University.- Maria Bedoya Toro Munera于2016年1月成为我们的监管事务和质量保证高级副总裁。Bedoya Toro Munera博士在制药行业的监管合规、质量控制和质量保证方面拥有超过30年的经验。从2014年到2015年被出售给Celgene，Bedoya Toro Munera博士担任Receptos Inc.的监管事务和质量保证高级副总裁。Receptos，Inc.之前，2007年6月至2014年1月，Bedoya Toro Munera博士担任Santarus，Inc.监管事务和质量保证高级副总裁。她此前曾担任Eisai Medical Research Inc.的监管事务高级总监（从2006年11月到2007年5月），从Ligand Pharmaceuticals，Inc.跳槽到Eisai，当时Ligand于2006年11月将其肿瘤产品剥离给Eisai。2003年至2006年，Bedoya Toro Munera博士担任Ligand全球监管事务和合规高级总监。从2000年到2003年，她担任Baxter Hyland Immuno的全球监管事务总监。从1998年到2000年，她在BASF BioResearch Corporation担任监管事务/质量总监，从1996年到1998年，她在Amylin Pharmaceuticals担任质量保证和监管合规总监。从1988年到1996年，Bedoya Toro Munera博士在Rhone-Poulenc Rorer工作，在法规合规、质量保证、质量控制和合规方面担任多个日益负责的职位。Bedoya Toro Munera博士拥有芝加哥大学工商管理硕士学位，俄亥俄大学生物分析化学博士学位。此外，她拥有西密歇根大学生物分析化学硕士学位和化学学士学位。
- Maria Bedoya Toro Munera became Dermata Therapeutics, Inc.'s Senior Vice President of Regulatory Affairs and Qualit Assurance in January 2016. Dr. Bedoya Toro Munera has more than 30 years of experience in regulatory compliance, quality control and quality assurance within the pharmaceutical industry. From 2014 until its sale to Celgene in 2015, Dr. Bedoya Toro Munera served as Senior Vice President, Regulatory Affairs and Quality Assurance at Receptos Inc. Prior to Receptos, Inc., Dr. Bedoya Toro Munera served as Senior Vice President of Regulatory Affairs and Quality Assurance at Santarus, Inc. from June 2007 to January 2014. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc., from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya Toro Munera worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006. From 2000 to 2003, she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000, Dr. Bedoya Toro Munera worked at BASF Bioresearch Corporation as Director, Regulatory Affairs/Quality, and from 1996 to 1998, she worked as Director, Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996, Dr. Bedoya Toro Munera worked at Rhone Poulenc Rorer in a number of increasingly responsible positions in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya Toro Munera holds an M.B.A. from the University of Chicago, and a Ph.D. in bio analytical chemistry from Ohio University. In addition, she has a M.A. in bio analytical chemistry and a B.S. in chemistry from Western Michigan University.
- Kyri K. Van Hoose
Kyri K. Van Hoose于2021年9月成为Dermata Therapeutics, Inc.高级副总裁兼首席财务官。Van Hoose女士是一位经验丰富且具有协作性的财务和会计专业人士，拥有20多年的经验，其中包括在生命科学行业拥有15年以上的会计和财务经验。Van Hoose女士在加入Dermata公司之前，于2020年9月至2021年4月在TEGA治疗公司（一家私营生物技术公司）担任首席财务官。在加入TEGA之前，2019年11月至2020年4月，Van Hoose女士担任Curzion制药公司的财务主管，该公司是一家私营罕见病公司，直到2020年4月被Horizon Therapeutics plc收购。Van Hoose女士还于2017年12月至2019年7月在临床阶段的生物技术公司Avelas Biosciences，Inc.任职。2005年9月至2016年2月，Van Hoose女士在Acadia Pharmaceuticals，Inc.担任领导职务，包括财务高级总监和公司财务总监。Van Hoose女士的职业生涯始于德勤，是一名持牌注册会计师（加利福尼亚州非在职）。Van Hoose女士在南加州大学获得会计学学士学位，在加州大学欧文分校获得金融硕士学位。
Kyri K. Van Hoose became Dermata Therapeutics, Inc.'s Senior Vice President and Chief Financial Officer in September 2021. Ms. Van Hoose is a seasoned and collaborative professional with over 25 years of experience. Prior to joining Dermata, from September 2020 to April 2021, Ms. Van Hoose served as Chief Financial Officer of TEGA Therapeutics, Inc., a private biotechnology company. Prior to TEGA, from November 2019 to April 2020, Ms. Van Hoose served as the head of finance for Curzion Pharmaceuticals, Inc., a private, rare disease company, until its acquisition by Horizon Therapeutics plc in April 2020. Ms. Van Hoose also served as head of finance at Avelas Biosciences, Inc., a clinical stage biotechnology company from December 2017 to July 2019. From September 2005 to February 2016, Ms. Van Hoose held leadership positions of increasing responsibilities at Acadia Pharmaceuticals, Inc., including Senior Director of Finance and Corporate Controller. Ms. Van Hoose began her career at Deloitte and is a licensed Certified Public Accountant (California inactive). Ms. Van Hoose earned her B.S. in Accounting at the University of Southern California and M.B.A. at the University of California, Irvine.- Kyri K. Van Hoose于2021年9月成为Dermata Therapeutics, Inc.高级副总裁兼首席财务官。Van Hoose女士是一位经验丰富且具有协作性的财务和会计专业人士，拥有20多年的经验，其中包括在生命科学行业拥有15年以上的会计和财务经验。Van Hoose女士在加入Dermata公司之前，于2020年9月至2021年4月在TEGA治疗公司（一家私营生物技术公司）担任首席财务官。在加入TEGA之前，2019年11月至2020年4月，Van Hoose女士担任Curzion制药公司的财务主管，该公司是一家私营罕见病公司，直到2020年4月被Horizon Therapeutics plc收购。Van Hoose女士还于2017年12月至2019年7月在临床阶段的生物技术公司Avelas Biosciences，Inc.任职。2005年9月至2016年2月，Van Hoose女士在Acadia Pharmaceuticals，Inc.担任领导职务，包括财务高级总监和公司财务总监。Van Hoose女士的职业生涯始于德勤，是一名持牌注册会计师（加利福尼亚州非在职）。Van Hoose女士在南加州大学获得会计学学士学位，在加州大学欧文分校获得金融硕士学位。
- Kyri K. Van Hoose became Dermata Therapeutics, Inc.'s Senior Vice President and Chief Financial Officer in September 2021. Ms. Van Hoose is a seasoned and collaborative professional with over 25 years of experience. Prior to joining Dermata, from September 2020 to April 2021, Ms. Van Hoose served as Chief Financial Officer of TEGA Therapeutics, Inc., a private biotechnology company. Prior to TEGA, from November 2019 to April 2020, Ms. Van Hoose served as the head of finance for Curzion Pharmaceuticals, Inc., a private, rare disease company, until its acquisition by Horizon Therapeutics plc in April 2020. Ms. Van Hoose also served as head of finance at Avelas Biosciences, Inc., a clinical stage biotechnology company from December 2017 to July 2019. From September 2005 to February 2016, Ms. Van Hoose held leadership positions of increasing responsibilities at Acadia Pharmaceuticals, Inc., including Senior Director of Finance and Corporate Controller. Ms. Van Hoose began her career at Deloitte and is a licensed Certified Public Accountant (California inactive). Ms. Van Hoose earned her B.S. in Accounting at the University of Southern California and M.B.A. at the University of California, Irvine.
- Gerald T. Proehl
Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
Gerald T. Proehl became a director and Dermata Therapeutics, Inc.'s President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc.'s Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical industry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). Mr. Proehl was selected as an officer and director due to his leadership experience at other companies and his history of founding and operating specialty pharmaceutical companies.- Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
- Gerald T. Proehl became a director and Dermata Therapeutics, Inc.'s President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc.'s Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical industry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). Mr. Proehl was selected as an officer and director due to his leadership experience at other companies and his history of founding and operating specialty pharmaceutical companies.